IFN-Is were extensively tested in COVID-19 and were uniformly found to be safe without adverse consequences, and multiple studies provided suggestive evidence of clinical efficacy [48,49,50,51,52,53,54,55]. This evidence concerns the gene IFNA1 and COVID-19.